Comparative Pharmacology
Head-to-head clinical analysis: HALOTESTIN versus ORA TESTRYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTESTIN versus ORA TESTRYL.
HALOTESTIN vs ORA-TESTRYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
Testosterone replacement therapy; binds to androgen receptors, promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
Intramuscular injection: 50-100 mg every 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
Terminal half-life 2.5-3.5 hours; clinical context: requires multiple daily dosing to maintain steady-state levels
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Renal (90% as glucuronide and sulfate conjugates, 10% unchanged); Biliary/fecal (10%)
Category C
Category C
Androgen
Androgen